VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Choueiri on the Biology of the CABOSUN Trial for RCC

Toni K. Choueiri, MD
Published: Monday, Aug 21, 2017



Toni K. Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses the findings of the CABOSUN trial for patients with metastatic renal cell carcinoma (mRCC).

The CABOSUN trial investigated cabozantinib (Cabometyx) versus sunitinib (Sutent) in patients with mRCC.

According to Choueiri, it is interesting to see that something that makes sense biologically was able translate to clinical outcomes. Cabozantinib appeared to be superior to sunitinib, which is what was seen in the results of the study, explains Choueiri.
 


Toni K. Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses the findings of the CABOSUN trial for patients with metastatic renal cell carcinoma (mRCC).

The CABOSUN trial investigated cabozantinib (Cabometyx) versus sunitinib (Sutent) in patients with mRCC.

According to Choueiri, it is interesting to see that something that makes sense biologically was able translate to clinical outcomes. Cabozantinib appeared to be superior to sunitinib, which is what was seen in the results of the study, explains Choueiri.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x